fig2
![MYC inhibitors in multiple myeloma](https://image.oaes.cc/8ae563b4-68be-4c6b-a5e3-2041b032c49d/4264.fig.2.jpg)
Figure 2. Examples of the most common resistance mechanisms to multiple myeloma therapies. See text for details. For a more thorough description of the resistance mechanisms, check the review from Wallington-Beddoe[32]. Figure adapted from[32]. CD38: Cluster of differentiation 38; CRBN: cereblon; ERK: extracellular signal-regulated kinases; IMiDs: immunomodulatory agents; IL-6: interleukin-6; MEK: mitogen-activated protein kinase; RAF: rapidly accelerated fibrosarcoma; SDF-1: stromal cell-derived factor; SLAM7: signaling lymphocytic activation molecule family member 7; TNFα: tumor necrosis factor alpha; Ub: ubiquitin; VEGF: vascular endothelial growth factor.